Showing posts with label Australia. Show all posts
Showing posts with label Australia. Show all posts

Australia Orthopedic Devices Market Outlook to 2016 now available at ReportsandReports

Original Source: Orthopedic Devices Market

Buy Now: Market Research

Dallas, TX: ReportsandReports announce it will carry Australia Orthopedic Devices Market Outlook to 2016 Market Research Report in its Store.

GlobalData’s medical equipment report, “Australia Orthopedic Devices Market Outlook to 2016” provides key market data on the Australia orthopedic devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – Orthobiologics, Joint Reconstruction, Spinal Surgery, Trauma Fixation, Arthroscopy, Orthopedic Accessories, and Orthopedic Braces and Supports. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope
  • Market size and company share data for seven orthopedic devices market categories – Orthobiologics, Joint Reconstruction, Spinal Surgery, Trauma Fixation, Arthroscopy, Orthopedic Accessories, and Orthopedic Braces and Supports.
  • Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2002 to 2009, forecast forward for 7 years to 2016.
  • 2009 company shares and distribution shares data for each of the seven market categories.
  • Global corporate-level profiles of key companies operating within the Australia orthopedic devices market.
  • Key players covered include DePuy, Stryker, Zimmer, Synthes, Medtronic, Smith & Nephew and Biomet.
Reasons to buy
  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Australia orthopedic devices competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.






Related Reports:






About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , |

ReportsandReports – Australia Shipping Report Q4 2010

Browse the complete Report on: Australia Shipping Report Q4 2010
Browse All Business Monitor International Market Research Reports
BMI's core view that mining companies will seek to gain ownership of freight networks such as railway lines and ports to complement their business operations and ensure their supply chain has once again been highlighted by mining companies BHP Billiton and Hancock Coal pledging to invest in new coal terminals at Australia's Abbot Point. The expansion project, like others at Australia's coal export terminals, has been driven by growing Chinese demand, which has seen vessels form queues outside New South Wales ports as demand intensifies and the country's port infrastructure struggles to cope. Although BMI believes that China's coal demand is a phenomenon that will last throughout the mid term, we are worried about the effect that a fall in Chinese coal demand in the short term will have on Australia's port expansions, as developers faced with falling coal throughput volumes may question the need for further investment.
By 2011, capacity at the port is set to be lifted from the current 21mn tonnes per year to 50mn tonnes per year. BHP Billiton and Hancock Coal plan to build two new terminals at the port, a project that when completed will see Abbot Point offering a coal export capacity of 110mn tonnes per annum. The port's management hopes to develop Abbot Point into the largest coal port in Australia and the world within 10 years, which would require significant expansion work. According to data from Ports Australia, Abbot Point is ranked fourth out of Australia's top coal export ports, handling 14.4mn tonnes of coal in the 2008/2009 financial year.
We expect cargo handled at two of Australia's key ports, the Port of Melbourne (POM) and Port of Sydney (POS), have grown at a slow to moderate rate in the financial year 2009/10. In general tonnage terms, POM will be out in front, with 5.2% growth to 30.61mn tonnes, starting to recover from the 2008/09 downturn when the port was not able to sidestep the effects of the international recession (volumes fell by 5.6% to 29.1mn tonnes in 2008/09). 2009/10 total volume at POS is expected to gain a more subdued 2.5% to 28.49mn tonnes. In 2008/09, POS volumes dropped by 4.7% to 27.8mn tonnes. At the Port of Melbourne container movements will grow 7.4% to 2.320mn 20-foot equivalent units (TEUs) this year, while at Port of Sydney they will be up by 4% to 1.855mn TEUs. While POS's growth has been consistently positive in recent years, POM has been more volatile, and more closely linked to international shipping fluctuations; 2008/09 box throughput at Port of Melbourne declined by 4.3%.
Affected by the global downturn, Australia's total trade fell by an estimated 4.44% in real terms in 2009 and we see a 4.9% rebound in 2010, followed by 4.2% decline in 2011. This year imports will grow more strongly than exports in real terms (6.0% vs 3.2%). The desired export-led recovery may not materialise for some time yet, as we expect Chinese demand to slow at the end of 2010 and into 2011, as Beijing tries to deflate a property bubble we fear has emerged. In doing so, we see China's construction sector decrease its demand for steel, and, therefore, this will knock on to China's demand for iron ore and coal. This will, in turn, will hit Australia, which caters for China's commodity demands.
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/

Original Source : – Australia Shipping Market
Buy Now : Market Research Report

Read More
Posted by Unknown on
categories: , , , , , , , , , |

ReportsandReports – Australia Pharmaceuticals and Healthcare Report Q4 2010

Browse the complete Report on: Australia Pharmaceuticals and Healthcare Report Q4 2010

Browse All Business Monitor International Market Research Reports

The value of Argentina’s pharmaceutical market is calculated to have reached ARS12.64bn (US$3.37bn) in 2009. Through to 2014, we forecast a compound annual growth rate (CAGR) of 14.36% and 9.78% in local currency and US dollar terms, with the market value topping ARS24.72bn (US$5.37bn). The increased usage of generics and volume changes are expected to be the key drivers of market growth, with patented medicines’ share of the total market by value dropping from 56.5% in 2009 to 47.7% in 2014. In regional terms, Argentina remains the seventh most attractive market in the Americas region, with drawbacks including its challenging intellectual property (IP) and pharmaceutical pricing and procurement environments, not to mention the wider economic and political uncertainties.
Despite this, the reduced opportunities and continuing challenges facing pharmaceutical companies in developed global markets are increasingly resulting in acquisition activities in emerging markets. To this end, in June 2010, UK-based major GlaxoSmithKline (GSK) acquired Argentina's Laboratorios Phoenix in a move emphasising the company's aim of increasing its market share of pharmaceutical sectors in developing countries.
The US$253mn cash transaction, the latest in a string of deals in developing markets (GSK also acquired 9.9% stake in South Korea's Dong-A Pharmaceuticals recently), will also enable GSK to expand its regional revenues, as the local drugmaker is among the top ten nationally and is also one of the leading indigenous medicine exporters.
However, local players are also concerned over low levels of achievable profitability and threats this poses to their survival. They expected drug prices to increase by 14.5% during 2010, which is over ten percentage points below the government's forecast of cumulative inflation. Nevertheless, volume consumption of medicines in Argentina has increased significantly over the past decade, which should – to a degree – compensate for the gap between pharmaceutical and general consumer price rises.
On a wider political and economic front – and although we have recently upwardly revised GDP growth for 2010 – we expect the upcoming 2011 elections to be a key factor in shaping the wider economic landscape. While we do not see a reduction in public spending by the administration of President Cristina Fernández ahead of the election – in which her husband, Néstor Kirchner, is widely tipped to be a candidate – options to sustain such loose fiscal policy are fast running out. Having exhausted most of the domestic funding options, the Argentine government is now hoping to return to international capital markets for the first time since the notorious government default in 2001. Overall, Argentina remains a prime example of one of our core regional views, namely that those countries with elevated political risk profiles – especially in the form of prolonged economic mismanagement – are set to underperform their more business-friendly regional peers over the medium term.



About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.


Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/

Original Source : – Australia Pharmaceuticals and Healthcare  Market
Buy Now : Market Research Report


Original Source : – Australia Pharmaceuticals and Healthcare  Market


Buy Now : Market Research Report

Read More
Posted by Unknown on
categories: , , , , , , , , , , |

ReportsandReports – Australia Food and Drink Report Q4 2010

Browse the complete Report on: Australia Food and Drink Report Q4 2010

Browse All Business Monitor International Market Research Reports

BMI View: A mature market, in which we expect reduced consumer confidence in 2011 as a secondary Chinese slowdown and a growing public debt burden weigh on the economy, Australia’s food and drink industry lacks the pull of its Asian emerging market counterparts. That said, high existing consumption levels and susceptibility to higher-value, premium product launches – particularly in categories such as health and functional foods – ensure that expansion and marketing activity remains high as producers and retailers jostle for customers in a highly competitive marketplace.
Headline Industry Data
  • Mass Grocery Retail sales to increase by 22.9% to 2014, with the underdeveloped discount sector set to be the key driver of growth – sector sales forecast to increase by 39.7% over that period
  • Beer volume sales are forecast to increase by just 2.5% to 1,898mn litres in 2014, although value growth is set to outperform volume growth thanks to ongoing industry premiumisation
  • Per capita food consumption is forecast to increase by 2.6% in 2010, but growth is expected to drop to just 1% in 2011 as the Australian economy, and in turn consumer confidence, is hurt by a slowdown in Chinese demand
Key Trends
Dairy Industry Dynamism – National Foods has again demonstrated its commitment to the country, announcing in April 2010 that it was to invest an additional AUD5.5mn (US$5.1mn) in its milk processing plant in Malanda, Queensland, on top of the AUD1.2mn (US$1.1mn) already spent on the plant in the previous eight months. The company also plans to invest AUD55mn (US$49mn) expanding its Crestmead dairy plant. These investments can be seen as an effort by the company to remain competitive amid increasingly tough operating conditions. Also in this vein, in May, Murray Goulburn Cooperative (MGC) entered into a joint venture with French multinational Danone in a bid to improve its ability to compete and manage volatile dairy prices, while also lifting its domestic competitive position. By entering Australia, Danone will benefit from the high-spending market.
Foster’s Comes To A Decision – After much speculation over what Foster’s Group would do with its underperforming wine business it announced that it would be completely demerging its beer and wine divisions. It is expected that Foster’s beer unit will receive particular attention from potential takeover partners. While the Australian beer market is a mature one, which does not allow for explosive growth opportunities, it still represents a valuable asset in any multinational brewer’s portfolio due to high
existing spending levels and a 104.7-litre annual per capita beer consumption rate. As such, this development is likely to generate significant competition in what is already an intensely competitive industry as brewers compete to land a market leader.
Key Risks To Outlook
A secondary slowdown in China would weigh on demand for Australian exports, in turn impacting domestic economic growth and consumer confidence and spending. Furthermore, there is the risk that a slump in house prices would negatively impact the discretionary spending levels of heavily-indebted Australian consumers.
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/
http://reportsandreports.proarticles.co.uk/
http://reportsnreports.wordpress.com/

Original Source : Market Research

Read More
Posted by Unknown on
categories: , , , , , , , , |

ReportsandReports – Australia Infrastructure Report Q4 2010

Browse the complete Report on: Australia Infrastructure Report Q4 2010

Browse All Business Monitor International Market Research Reports

BMI View: Australia’s infrastructure sector is our top pick of the developed markets we cover, due to strong fundamentals for long-term opportunities and a high level of sophistication in terms of project finance operations and business environment. However, we believe a near-term Chinese slowdown will put a damper on Australia’s real infrastructure and construction industry value growth for the remaining of 2010 and the whole of 2011. Consequently, we have revised down our construction industry forecast for 2011, with real growth of 1.4% now anticipated year-on-year (y-o-y), to reflect this slowdown, but expect upside potential during the latter stage of our forecast period, with annual average construction industry real growth of 3.8% anticipated between 2013 and 2018.
Key factors influencing growth for the next quarter included:
Two factors driving new transportation infrastructure investments are China’s insatiable demand for mining exports and the subsequent demand for freight transport services. However BMI’s anticipation of a slowdown in Chinese economic growth is likely to impact Australian raw materials exports, thereby decreasing the demand for infrastructure. As such we have revised our transport infrastructure forecasts downwards to reflect this deceleration.
The Australian government’s plans to privatise and lease a number of freight transport assets is gaining interest – eg the bidding for the Port of Brisbane. Besides public assets, infrastructure funds have also shown interest in purchasing private infrastructure assets – eg Canada Pension Plan Investment Board (CPPIB)’s takeover offer of Intoll Group. We believe these major infrastructure funds are looking to gain from the long term potential of Australia’s infrastructure sector.
BMI's new data series for Australia's residential and non-residential building industry value indicate that real growth for the sector's value will moderate significantly in 2011 following a tentative recovery in 2010. Combined with our view that the Australian economy is due for a period of underperformance over the coming year, especially on the back of a correction in real estate valuations, we are raising our concern for industry players in the residential and nonresidential building industry over the shorter term.
Australia was one of the first countries to embark on the public private partnership (PPP) scheme and use private funding to develop infrastructure projects. As a result, it has the most sophisticated market for PPP schemes in the world, according to BMI’s Project Finance Ratings. Australia’s score of 77.2 out of 100 reflects a stable and well organised political system, sophisticated financial infrastructure, a competitive operating environment and a transparent and coherent regulatory environment. For BMI’s Infrastructure Business Environment Ratings, Australia achieved a score of 73.8 out of 100, gaining the top spot in the regional table for developed states. The combination of the country’s sizable growth potential in the infrastructure industry, low risks in its operating environment, and coherent strategy for infrastructure investment gives Australia the best risk/rewards profile for investors among the developed states.

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

Contact:


Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/

http://reportsandreports.proarticles.co.uk/

http://reportsnreports.wordpress.com/

Read More
Posted by Unknown on
categories: , , , , , , , , , |

ReportsandReports – Australia Agribusiness Report Q4 2010

Browse the complete Report on - Australia Agribusiness Report Q4 2010

Browse All Business Monitor International Market Research Reports

at http://www.reportsandreports.com/Publishers/business-monitor-international/

BMI View: Australia will see growth across all agricultural sectors following the global economic recovery, with demand primarily led by Asian emerging markets. As a developed state, Australia will not expect to see large consumption increases. Despite this, Australian exports should see increased export opportunities through free trade agreements, particularly with its regional peers and Middle Eastern markets.
Key Forecasts - Wheat production growth to 2013/14: 25%. Wheat consumption growth to 2014: 13%. Australia's signature export good will show strong production increases owing to increased deregulation in the sector and enhanced export opportunities, particularly to the Middle East. Given the recent spike in wheat prices, Australia wheat exports stand to gain, especially on the back of an estimated year-on-year (y-o-y) increase in production by 4.2% for 2010.
A surge in rice-consuming Asian immigrants combined with increased interest in foreign foods should see rice gain in popularity. Assuming the rate of growth of immigrants, rice consumption growth to 2013/14: 21%.
Milk production growth to 2014: 12% and consumption growth to 2014: 6%. Consumption growth will be driven mainly by population growth, since at close to 110kg per year, Australia already has one of the highest global per capita milk consumption rates. - 2010 Real GDP Growth: 2.3% (up from 1.4% in 2009; predicted to average 2.3% from 2009 to 2014).
Real Interest (cash rate eop): 4.25%. Up from 3.75% eop in 2009. Industry Developments
Experiments are underway to produce rice in areas outside of the Riverina - the main rice growing regionwhere irrigation is not necessary. Another potential avenue for the expansion of rice production is the Ord River Irrigation Area in the remote Kimberley region of Western Australia. The US$390mn project will bring around another 12,000 hectares of land under cultivation, with the first parcels being sold off in 2011.
Canadian fertiliser giant Agrium has offered to buy the Australian Wheat Board (AWB) straight up for US$1.1bn in an all cash deal on August 18. For the recently privatised AWB, the move would help fulfill a goal of joining forces with a global player after its monopoly over Australian wheat exports was recently revoked in 2008. And on July 6, Indonesian Wilmar International, the world's largest palm oil producer, agreed to buy Sucrogen, a major Australian sugar producer for US$1.75bn, in a bid to pursue growth strategies in Asian markets which synergise its operations.
Despite the 2010 Australian elections resulting in a hung parliament at the time of this writing, BMI notes that there are more rural politicians being represented in the government as independent seat holders. Consequently, it is possible for these politicians who are usually more pro-farmer, to lobby for more protectionist policies to be passed in the next few years. This will be intended to boost purchases of domestically produced agricultural products which have been facing stiff competition from cheaper imports.


About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)


Contact:

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/

http://reportsandreports.proarticles.co.uk/

http://reportsnreports.wordpress.com/

Read More
Posted by Unknown on
categories: , , , , , , , , |

ReportsandReports – Australia Commercial Banking Report Q4 2010

Browse the complete Report on – Australia Commercial Banking Report Q4 2010

Browse All Business Monitor International Market Research Reports

at http://www.reportsandreports.com/Publishers/business-monitor-international/

Since Q108, we have described numerically the banking business environment for each of the countries surveyed by BMI. We do this through our Commercial Banking Business Environment Rating (CBBER), a measure that ensures we capture the latest quantitative information available. It also ensures consistency across all countries and between the inputs to the CBBER and the Insurance Business Environment Rating, which is likewise now a feature of our insurance reports. Like the Business Environment Ratings calculated by BMI for all the other industries on which it reports, the CBBER takes into account the limits of potential returns and the risks to the realisation of those returns. It is weighted 70% to the former and 30% to the latter.
The evaluation of the Limits of Potential Returns includes market elements that are specific to the banking industry of the country in question and elements that relate to that country in general. Within the 70% of the CBBER that takes into account the Limits of Potential Returns, the market elements have a 60% weighting and the country elements have a 40% weighting. The evaluation of the Risks to Realisation of Returns also includes banking elements and country elements (specifically, BMI’s assessment of long-term country risk). However, within the 30% of the CBBER that takes into account the risks, these elements are weighted 40% and 60%, respectively.
Further details on how we calculate the CBBER are provided at the end of this report. In general, though, three aspects need to be borne in mind in interpreting the CBBERs. The first is that the market elements of the Limits of Potential Returns are by far the most heavily weighted of the four elements. They account for 60% of 70% (or 42%) of the overall CBBER. Second, if the market elements are significantly higher than the country elements of the Limits of Potential Returns, it usually implies that the banking sector is (very) large and/or developed relative to the general wealth, stability and financial infrastructure in the country. Conversely, if the market elements are significantly lower than the country elements, it usually means that the banking sector is small and/or underdeveloped relative to the general wealth, stability and financial infrastructure in the country. Third, within the Risks to Realisation of Returns category, the market elements (ie: how regulations affect the development of the sector, how regulations affect competition within it, and Moody’s Investors Service’s ratings for local currency deposits) can be markedly different from BMI’s long-term risk rating.


About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)


Contact:

Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://reportsandreports.blogspot.com/

http://reportsandreports.proarticles.co.uk/

http://reportsnreports.wordpress.com/ 

Read More
Posted by Unknown on
categories: , , , , , , , , |

ReportsandReports - The Australian Pharmaceutical Market Outlook to 2015: Policy environment, market analysis, key trends, growth opportunities and competitive landscape



Australia is the most attractive market for pharmaceutical investment in the Asia Pacific region which is primarily due to its growing and ageing population, excellent access to medicines, and fast-recovering economy.

Life expectancy in Australia is 79.2 years for males and 84.1 years for female which is among the highest in the world. High life expectancy amongst Australians has led to an increase in lifestyle diseases resulting in an increase in healthcare spending. In 2009, cancer, cardiovascular diseases, diabetes, respiratory diseases (COPD, Asthma), musculoskeletal disease, neurological disorders (dementia), mental disorders, remained the leading cause of health problems in the country.
Funding for health goods and services in Australia comes from various sources such as the Australian government, local governments and non government agencies. In 2005-06 period, the major funding came from two levels of government, which accounted for 68% of the total healthcare expenditure. Australian federal government followed by local government was the major contributors accounting for 43% and 25% of the total funding respectively (AIHW).

The Therapeutic Goods Act of 1989 is the core of market regulation in Australia. The objective of this act is to ensure that Australians get medicines and medical devices which are safe and are of high quality, and match standards equal to that of comparable countries. This act also provides a nation wide regulatory outline for therapeutic goods and ensures the quality, safety, and efficacy of medicines and medical devices. All medical products which come in or are exported from Australia are registered with the ARTG (Australian Register of Therapeutic Goods).

Key features of this report
  • Macroeconomic environment in Australia includes the demographic trends, economic landscape, disease burden and healthcare spending
  • Australian healthcare system involving the pharmaceutical spending, intellectual property regime, pricing and reimbursement, healthcare reforms, and recent development in the healthcare sector
  • Overview of the Australian pharmaceutical market covering comparative dynamics of major pharmaceutical market, key recent events, therapeutic area analysis, leading product dynamics, generic drug market and the overall market forecast through 2015
  • Forecasts and analysis of the leading products in the Australian pharmaceutical market over the period 2009–15 spread across major indications and classes of treatments
Scope of this report
  • Develop insights for the Australian pharmaceutical market, pricing & regulation, healthcare system and detailed epidemiological status of the common indications/risk factors in the country
  • Quickly understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive challenges in the Australian market
  • Gain up-to-date competitive intelligence across a wide-range of marketed products, R&D pipeline, market share data, sales forecast and competitive landscape for the major players in the Australian pharmaceutical market
  • Compare the franchises of leading pharmaceutical players across major indications, and understand how market share of leading companies will change in the next 6 years

Key Market Issues
  • The Australian economy grew by 1.5% during the first three quarters of 2009: In 2009, a fiscal stimulus package of over $50bn was introduced to reduce the effect of slowing world economy by the Executive Government of Australia under prime ministership of Kevin Rudd. Increasing demand for commodities from China along with the policy reforms done by the government has helped Australian economy regain buoyancy after just one quarter of decline in growth. The Australian economy grew by 1.5% during the first three quarters of 2009, which was the best performance in OECD (Organization for Economic Co-operation and Development).
  • New PBS reforms, insulates certain drugs from reference pricing: Recent changes in the pricing policy shows a shift towards rewarding innovation. Since August 2007, the PBS has been divided into two formularies F1 and F2. F2 drugs will have the price cuts whereas F1 drugs are insulated from reference pricing, even if the mechanism of action of a F1 dug is similar to that in F2. F1 drugs which do not have bioequivalent brands can maintain higher prices according to the new formularies.
  • Australian government approved 45% refundable tax credit for R&D companies: Biotechnology research in Australia continues to receive funding from both federal and state governments in Australia (New Zealand trade and enterprise report, January 2009). Apart from the Australian government’s Innovation Investment Follow-on Fund (IIFF, a venture capital fund) in May 2009, the government approved the 45% refundable tax credit for R&D, applicable for companies with a turnover of under $16.7m (Australian dollar, (AUD) 20m). Moreover, IIFF is targeted to address the lack of capital available to the most promising and innovative companies.
Key findings from this report
  • According to 2008 AIHW (Australian Institute of Health and Welfare) report, high life expectancy (second only to Japan) and an increasingly aged population has led to an increase in lifestyle diseases resulting in an increase in healthcare spending. Approximately one in every five adult Australians (nearly 4m people) has some or the other disability and more than 1m people need assistance with their daily activities.
  • The Australian pharmaceutical market was valued at around $9bn in 2009 and includes both domestic manufacturers and large pharmaceutical companies, with the latter having a direct base in the country through R&D and marketing. Among foreign players, Pfizer, AstraZeneca, Sanofi-Aventis and Novartis dominated the Australian pharmaceutical market in 2009.
  • Cardiovascular disorders, led by Lipitor (Pfizer) and Crestor (AstraZeneca) remained the major therapeutic area in the Australian pharmaceutical market. Cholesterol and triglyceride regulating preparations, angiotensin II inhibitors, ACE inhibitors (plain), were the leading drug classes in the cardiovascular therapy in 2009.
  • CNS disorders, led by Zyprexa (Eli Lilly) remained the other leading therapy area in the Australian pharmaceutical market. Antipsychotics, anti-depressants, and mood stabilizers were the major drug classes in this therapy area registering over $250m sales each in 2009.
Key questions answered
  • What will be the major growth indications and the accompanying growth drivers in the Australian pharmaceutical industry over the next 6 years?
  • Which were the leading players in the Australian pharmaceutical market (both multinational and domestic) in 2009?
  • Which products will be the future growth drivers for the Australian pharmaceutical market?
  • Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2009–15?
  • How is the competitive landscape of key therapeutic areas in Australia?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , |

Casino Field, Australia, Commercial Asset Valuation and Forecast to 2017 now available at ReportsandReports

Dallas, TX: ReportsandReports announce it will carry Casino Field, Australia, Commercial Asset Valuation and Forecast to 2017 Market Research Report in its Store.

Browse complete Report on:   http://reportsandreports.com/market-reports/casino-field-australia-commercial-asset-valuation-and-forecast-/

The Casino field is an offshore gas field, located approximately 250km south-west of Melbourne in the Otway Basin. It lies in the VIC/P44 permit, 29km southwest of Port Campbell. The water depth in the region is approximately 70m. The operator of the field is Santos.
Santos is the major equity holder of the Casino field with 50% equity share. AWE and Mitsui are the other two equity partners. Santos is one of the leading gas producing companies of Australia. It has been active in the energy business for more than 50 years.
The Casino field produces mainly natural gas with a small quantity of condensate. The natural gas from Casino field contains approximately 94% methane and is very low in carbon dioxide content (less than 1%). It has minimal associated hydrocarbon liquids.
The production from the Casino field started in February 2006 with the production of around 88.30 million cubic feet per day of natural gas and 96 barrels per day of condensate. The field produced 126.74 billion cubic feet of gas and 121.79 thousand barrels of condensate until 2009. The current production from the field (2010) is estimated at 24.70 billion cubic feet of gas and 9.36 thousand barrels of condensate.
The production life of the Casino field is expected to be around 12 years with complete abandonment during 2017. The field is expected to generate $1.12 billion in revenues (undiscounted) during its remaining life (starting January 1, 2010) and is expected to yield an Internal Rate of Return (IRR) of around 24.33%.

Scope

  • The report provides detailed information on oil and gas production, infrastructure, reserves, geology, operator and equity partners and the latest fiscal terms applicable to the asset and provides its fair value (Remaining Net Present Value) based on remaining reserves, forecast production, capital and operational costs, fiscal regime and commodity prices.
  • The report also provides additional valuation parameters like Internal Rate of Return (IRR), Profitability Index (PI), Pay Back (discounted and undiscounted), Entitlement Production (EP) and Working Interest (WI) to enhance your decision making process.
  • This report provides detailed sensitivity analysis of the remaining NPV with changes in the commodity prices, discount rate, production and key fiscal terms.
  • Detailed cash flows over the life of the asset are included in the report. These cash flows cover a wide range of calculations related to various payments to the government/licensing authority.
  • Interactive Excel models can be used to derive custom valuations, sensitivities and cash flows based on the specific inputs by the user in the model. These custom inputs vary from production data, cost information, price information and fiscal terms information.
Reasons to buy
  • Make well informed investment decisions based on detailed operational analysis and cash flow forecasts
  • Estimate the fair value of your future investment under different economic and fiscal conditions
  • Value a prospective investment target through a comprehensive analysis using focused forecasting and valuation methodologies.
  • Supporting interactive excel model will enhance your decision making capability in a more rapid and time sensitive manner
  • Evaluate how the changes in the country’s fiscal policies impact the cash flows and the present value of the asset
1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4
2 Casino Field, Australia, Introduction 5
3 Casino Field, Australia, Geology and Formation 7
4 Casino Field, Australia, Equity Partners 9
5 Casino Field, Australia, Crude Oil Reserves 9
6 Casino Field, Australia, Key Fiscal Terms 10
6.1 Royalty 10
6.2 Fees 10
6.3 Petroleum Resource Rent Tax 10
6.4 Taxation 10
6.5 Deductions and Depreciation 11
6.6 Withholding Tax 11
6.7 Ring Fence 11

7 Casino Field, Australia, Infrastructure 11
7.1 Upstream Infrastructure 11
7.1.1 Wells 11
7.1.2 Iona Onshore Gas Storage Facility 11
7.2 Midstream Infrastructure 13
7.2.1 Pipeline and Shore Crossing 13

8 Casino Field, Australia, Development Plan, Investment and Expenditure 16
9 Casino Field, Australia, Natural Gas Production 18
10 Casino Field, Australia, Field Economics 20
10.1 Casino Field, Economic Assumptions 20
10.1.1 Forecast Commodity Prices 20
10.1.2 Inflation 20
10.1.3 Discount Rate and Representation of Cash Flows 20
10.1.4 Sensitivity 20
10.1.5 Access to the Economic Model 20
10.2 Casino Field, Cash Flow Analysis 21
10.2.1 Remaining NPV Sensitivity to Discount Rates and Commodity Prices 22
10.2.2 Remaining NPV Sensitivity to Change in Commodity Prices and Production Rates 23

11 Casino Field, Australia, Summary Cash Flows 25
11.1 Casino Field, Australia, Front End Load Due To Fiscal Policy 25
11.2 Casino Field, Australia, Tax Liability 26

12 Appendix 28
12.1 Methodology 28
12.2 Coverage 28
12.3 Secondary Research 28
12.4 Primary Research 28
12.5 E&P Forecasts 29
12.6 Capital Costs 29
12.7 Exploration and Appraisal (E&A) Costs 29
12.8 Operating Costs 29
12.9 Expert Panel Validation 30
12.10 About GlobalData
12.11 Contact Us
 12.12 Disclaimer

Browse complete Report on :  http://reportsandreports.com/market-reports/casino-field-australia-commercial-asset-valuation-and-forecast-/

Browse all Energy and Power Market Research Reports
Browse all  GlobalData Market Research Reports
Browse all Latest Report

Related Reports:
Amal Oil Field (Redevelopment), Libya, Commercial Asset Valuation and Forecast to 2017
Schiehallion field, United Kingdom, Commercial Asset Valuation and Forecast to 2017
Wanaea Field, Western Australia, Commercial Asset Valuation and Forecast to 2020

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Read More
Posted by Unknown on
categories: , , , , , , , , |

Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape now available at ReportsandReports

Dallas, TX: ReportsandReports announce it will carry Australia Pharmaceutical Market Overview – Reforms and continued price cuts will change the healthcare landscape Market Research Report in its Store.

Browse complete Pharmaceutical Market Report

Introduction

The prescription pharmaceutical market in Australia was valued at $9.1 billion in 2009. Key growth drivers include the growing use of chronic high-value innovative treatments driven by a rising elderly population and high public spending as a proportion of total healthcare expenditure.

Scope

* Overview of Australia’s socioeconomics and demographics, healthcare system, regulation, pricing and reimbursement and intellectual property position.

* Assesses the size of Australia’s pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies.

* Examines Australia’s generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion.

* Quantifies Australia’s R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis.

Highlights

Australia’s health expenditure totaled $81.8 billion, representing 9.1% of gross domestic product (GDP) in the financial year of 200708, which is the same percentage of GDP as the previous year. Australia’s health expenditure as a proportion of GDP has been comparable to that seen in Europe, with most of its spending coming from the government.

Lipitor (atorvastatin, Pfizer) generated significantly higher sales than any other brand on the Australian pharmaceutical market in 2009 ($550m). The second and third highest-selling brands, Crestor (rosuvastatin; AstraZeneca) and Nexium (esomeprazole; AstraZeneca), lag far behind Lipitor and did not even reach half of its sales.

Compared with Europe, where 17 biosimilars of five different molecules have been approved since 2006, Australia’s biosimilar market is small, particularly in terms of sales at $45,000. Somatropin is the only biologic that has biosimilar versions available, although the market is still very much dominated by the original branded product.

Reasons to Purchase

* Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access.

* Quantify the size and growth of the prescription pharmaceutical market in Australia, analyzing key therapy areas, brands and companies.

* Assess drivers and resistors of generic and biosimilars uptake in Australia and the level of erosion brands can expect to face post patent expiry.

Table Of Contents

ABOUT DATAMONITOR HEALTHCARE

About the Healthcare Strategic Analysis Team

Geographic-specific reports:

Global issue reports:

About the Healthcare Asia-Pacific Team

1. Australia – Executive Summary

Strategic scoping and focus

Key findings – healthcare drivers and resistors in Australia

Australia – Socio-demographic and economic analysis

Socio-demographic trends

Socio-economic trends

Australia – Healthcare system and drug regulatory analysis

Healthcare expenditure

Healthcare system overview

Regulatory issues

Pricing and reimbursement issues

Australia – Prescription pharmaceutical sales analysis

Pharmaceutical market size

Leading therapy areas

Leading prescription pharmaceutical brands

Leading pharmaceutical companies

Australia – Drug expiry analysis

Generics market

Brand erosion post patent expiry

Biosimilars market

Australia – Pharmaceutical industry infrastructure analysis

Pharmaceutical industry infrastructure overview

R&D infrastructure trends

Manufacturing infrastructure trends

Related reports

Upcoming related reports

Table of Contents

2. Australia – Socio-demographic and economic Analysis

Key findings

Socio-demographic trends

Socio-economic trends

Demographic trends in Australia

High population growth is a hot topic in Australia

Australia’s birth rate is expected to stabilize

Proportion of elderly individuals is set to rise

Australia’s life expectancy is one of the highest compared with other markets

Australia is a culturally and ethnically diverse country

Ischemic heart disease tops disease burden in Australia

Political climate in Australia

Federal elections are set for August 21, 2010

The 2010-11 Budget shows that the government’s priorities include reforms in health and hospitals

Memorandum of Understanding (MoU) is good for innovators, but not so good for generics companies

Fifth Community Pharmacy Agreement was received positively all around

Australia’s economy performs relatively well despite global downturn

Australia is doing comparatively well in the face of the global financial crisis

Unemployment rate experienced a small setback

Business environment in Australia

Corporate tax rate is high compared with other medium-sized OECD countries, but likely to be lowered

Unexpected price cuts led to uncertainty in Australia’s pharmaceutical business environment

Historically strong Australian biotechnology industry took a big hit from global downturn

3. Australia – Healthcare system and drug regulatory analysis

Key findings

Healthcare expenditure

Healthcare system overview

Regulatory issues

Pricing and reimbursement issues

Healthcare expenditure – Australia’s growth in pharmaceutical spending is under debate

Australia’s healthcare system

The structure of the Australian healthcare system is complex

Reforms aim to decrease complexity and inequalities by changing the funding and governance of health and hospitals

Government focuses on early intervention and the integration of care in the community

Medicare provides Australians with a range of free services

Medicare Australia funds and provides public healthcare services

Pharmaceutical Benefits Scheme (PBS) funds the use of prescription drugs

The Australian government promotes the uptake of private health insurance

GP Super Clinics will be established in order to improve access to primary care

Australia’s hospital system is split between a public and private market

Rural and Indigenous health are key focal points

National Medicines Policy aims to improve health outcomes through appropriate access to medicines

The Pharmaceutical Health and Rational Use of Medicines Committee and National Prescribing Service focus on quality use of medicines

Regulatory issues in Australia

Therapeutic Goods Administration (TGA) largely adopts EU standards

The Advisory Committee on Prescription Medicines (ACPM) has taken over from the Australian Drug Evaluation Committee (ADEC)

New organizational structure was put in place in mid-2010

New fees for the evaluation of prescription medicines

Therapeutic Goods Administration (TGA) reforms aim to reduce regulatory burden

Accelerated application entry and improved application coordination (streamlined submission process)

Increased transparency of prescription medicine regulatory process (the AusPAR project)

Improved access to prescription medicine information (the PI/CMI project)

The ‘biologicals framework’ refreshes regulations for biologicals

Intellectual property environment

Standard 20-year patent can be extended by up to 5 years

Data exclusivity is 5 years, during which ‘springboarding’ is allowed

Pricing reforms may encourage ‘evergreening’

Drug counterfeiting is less of a problem in Australia than in other developed markets

Drug importation is controlled by the government and patent holders

Drug reimbursement in Australia

Reimbursement is decided by the Pharmaceutical Benefits Advisory Committee (PBAC)

High level of evidence is needed for a drug to be added to reimbursement list

Transparency in PBAC decisions has improved

Probability of a positive PBAC outcome was 75% in 2009, but lower for major applications

Parallel applications to the TGA and PBAC will become possible from 2011

AUD10m ($7.9m) threshold for cabinet approval remains

Section 100 programs provide drugs under special arrangements

Drug pricing in Australia

Prices are negotiated by the Pharmaceutical Benefits Pricing Authority (PBPA)

Latest Pharmaceutical Benefits Scheme (PBS) reforms led to considerable drug price reductions

The price disclosure program singles out generics for further price cuts

Criticized ‘therapeutic groups’ have been put to a halt by the Memorandum of Understanding (MoU)

The PBPA uses different types of pricing models

Reference pricing method is mainly used for products in Formulary 1

Cost Plus method is mainly used for products in Formulary 2

Weighted Average Monthly Treatment Cost (WAMTC) is a key feature in therapeutic groups

Risk sharing agreements lack transparency

Special patient contributions apply in some cases

The Access to Medicines Working Group (AMWG) facilitates discussion between the government and pharmaceutical industry on PBS reforms

PBAC evaluates bDMARDs in cost-effectiveness review

Australian Government Productivity Commission highlights specific concerns about the regulation of medicines in Australia

Requirement for multiple ethics approvals

Timeliness and cost of manufacturing audits/GMP assessments

TGA transparency and communication

Concerns about PBS listing and pricing processes

Delays in achieving PBS listing due to overlapping processes

Concerns about marketing and advertising rules

Australia’s healthcare reforms

4. Australia – Prescription pharmaceutical sales analysis

Key findings

Pharmaceutical market size

Leading therapy areas

Leading prescription pharmaceutical brands

Leading pharmaceutical companies

Pharmaceutical market size in Australia

Leading therapy areas in Australia

Cardiovascular drugs hold the largest share of the Australian market value

Central nervous system products hold the second-largest share of the Australian market value

Musculoskeletal drugs exhibited the strongest growth in sales in 2005-09 and 2008-09

The hematology class experienced the most rapid decline in growth

Leading pharmaceutical brands in Australia

Lipitor achieved by far the highest sales in Australia in 2009, but generics are expected in 2012

Crestor experiences a huge uptake in sales but may face price cuts and uncertain patent protection

Nexium’s sales are going strong despite its price being linked to generic omeprazole

Leading companies in the Australian pharmaceutical market

Leading international companies active in Australia account for 63% of the pharmaceutical market

Leading Australian companies only make up 7% of the Australian pharmaceutical market

Sigma Pharmaceuticals

CSL

iNova Pharmaceuticals

5. Australia – Drug expiry analysis

Key findings

Generics market

Brand erosion post patent expiry

Biosimilars market

Australia generics market dynamics

Australia generics volume uptake

Australia generics value uptake

Drivers and resistors in the Australian generics market

Brand substitution is allowed if equivalence has been shown

Prevention of brand substitution by physicians is possible, but uncommon

Competing on price is difficult for generics manufacturers in Australia

High generics prices are targeted in continued price cuts

Pharmacists receive AUD1.50 for each script of a premium-free PBS drug they dispense

The Generic Medicines Industry Association (GMiA) unites key generics players

The National Prescribing Service (NPS) promotes generics education

Key generics players in Australia

Generic simvastatin is main single source of income for key generics players in Australia

Opportunities for the generics industry

Small molecule brand erosion in Australia

Overview of drugs analyzed

Mean level of brand erosion in Australia

Brand erosion in the Australian retail and hospital setting

Brand erosion by therapy area in Australia

Brand erosion by drug formulation in Australia

Biosimilars market dynamics in Australia

Drivers of biosimilar uptake – Australia bases its biosimilar approval pathway on that of the EU

Resistors of biosimilar uptake – limitations around reimbursement may cast a shadow over the commercial attractiveness of biosimilars in Australia

Somatropin is the only biosimilar available in Australia

Key players in the Australian biosimilars market

Monoclonal antibodies represent a major opportunity for the biosimilars industry

Over $400m in monoclonal antibody sales to go off-patent before 2015

However, branded monoclonal antibody uptake is currently hampered by reimbursement issues

International drivers and resistors to biosimilar monoclonal antibody uptake

Monoclonal antibody biosimilars in development internationally

6. Australia – Pharmaceutical industry infrastructure analysis

Key findings

Pharmaceutical industry infrastructure overview

R&D infrastructure trends

Manufacturing infrastructure trends

Overview of the pharmaceutical infrastructure in Australia

R&D and manufacturing strategies in Australia

Australia misses out as clinical trials are moved to Asia

Key company infrastructure in Australia

Pfizer

AstraZeneca

Sanofi-Aventis

GlaxoSmithKline

Novartis

Merck & Co.

Johnson & Johnson

Sigma Pharmaceuticals

Roche

Mylan

7. Bibliography

Australia – Executive Summary

Publications and online articles

Datamonitor reports and products

Australia – Socio-demographic and economic analysis

Publications and online articles

Australia – Healthcare system and drug regulatory analysis

Publications and online articles

Datamonitor reports and products

Australia – Prescription pharmaceutical sales analysis

Publications and online articles

Australia – Drug expiry analysis

Publications and online articles

Datamonitor reports and products

Australia – Pharmaceutical industry infrastructure analysis

Publications and online articles

APPENDIX

Exchange rate used in this report

Australia brand erosion – additional data

Australia brand erosion – methodology

Datamonitor prescription pharmaceutical definition and therapy area classification

About Datamonitor

About Datamonitor Healthcare

Datamonitor consulting

Disclaimer

Disclaimer

Browse complete Pharmaceutical Market Report

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports

Browse all Latest Report

Related Reports:

Australia Pharmaceuticals and Healthcare Report Q3 2010

Energy Market Landscape: Australia – Western Australia

Obama’s Healthcare Reform Bill and its Impact on the U.S. Healthcare Markets (Pharmaceuticals, Medical devices and Health insurance)

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Read More
Posted by Unknown on
categories: , , , , , , , , |